204 related articles for article (PubMed ID: 37163361)
1. Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia.
Roeker LE; DerSarkissian M; Ryan K; Chen Y; Duh MS; Wahlstrom SK; Hakre S; Yu L; Guo H; Mato AR
Blood Adv; 2023 Aug; 7(16):4291-4301. PubMed ID: 37163361
[TBL] [Abstract][Full Text] [Related]
2. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
[TBL] [Abstract][Full Text] [Related]
3. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
4. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC; Hillmen P; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Yenerel MN; Illés A; Kay N; Garcia-Marco JA; Mato A; Pinilla-Ibarz J; Seymour JF; Lepretre S; Stilgenbauer S; Robak T; Rothbaum W; Izumi R; Hamdy A; Patel P; Higgins K; Sohoni S; Jurczak W
J Clin Oncol; 2021 Nov; 39(31):3441-3452. PubMed ID: 34310172
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
[TBL] [Abstract][Full Text] [Related]
6. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke.
Narezkina A; Akhter N; Lu X; Emond B; Panjabi S; Forbes SP; Hilts A; Liu S; Lafeuille MH; Lefebvre P; Huang Q; Choi M
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):e959-e971. PubMed ID: 35973891
[TBL] [Abstract][Full Text] [Related]
7. An update on acalabrutinib to treat chronic lymphocytic leukemia.
Blackmon A; O'Brien S
Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
[TBL] [Abstract][Full Text] [Related]
8. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Thompson MC; Mato AR
Hematol Oncol Clin North Am; 2021 Aug; 35(4):793-806. PubMed ID: 34174986
[TBL] [Abstract][Full Text] [Related]
10. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP
Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069
[TBL] [Abstract][Full Text] [Related]
11. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
12. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.
Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Jacobs R
Patient Prefer Adherence; 2023; 17():2073-2084. PubMed ID: 37641660
[TBL] [Abstract][Full Text] [Related]
13. Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Seymour JF; Byrd JC; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Brown JR; Munir T; Mato A; Stilgenbauer S; Bajwa N; Miranda P; Higgins K; John E; de Borja M; Jurczak W; Woyach JA
Blood; 2023 Aug; 142(8):687-699. PubMed ID: 37390310
[TBL] [Abstract][Full Text] [Related]
14. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Wolska-Washer A; Robak T
Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
[TBL] [Abstract][Full Text] [Related]
15. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
[No Abstract] [Full Text] [Related]
16. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves.
Alrawashdh N; Persky DO; McBride A; Sweasy J; Erstad B; Abraham I
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e820-e831. PubMed ID: 34274291
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Pleyer C; Sun C; Desai S; Ahn IE; Tian X; Nierman P; Soto S; Superata J; Valdez J; Lotter J; Wiestner A
Leuk Lymphoma; 2020 Oct; 61(10):2375-2382. PubMed ID: 32508208
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database.
Vallabhaneni S; Adusumalli S; Wu J; Groeneveld PW; Gerson J; O'Quinn RP
Cardiooncology; 2024 Jun; 10(1):33. PubMed ID: 38824606
[TBL] [Abstract][Full Text] [Related]
19. BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL.
Mhibik M; Gaglione EM; Eik D; Kendall EK; Blackburn A; Keyvanfar K; Baptista MJ; Ahn IE; Sun C; Qi J; Rader C; Wiestner A
Blood; 2021 Nov; 138(19):1843-1854. PubMed ID: 34046681
[TBL] [Abstract][Full Text] [Related]
20. A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
Mato AR; Tang B; Azmi S; Yang K; Zhang X; Stern JC; Hedrick E; Huang J; Sharman JP
Haematologica; 2022 Nov; 107(11):2630-2640. PubMed ID: 35443563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
